My Personal CFO LLC’s AbbVie ABBV Stock Holding History

My Personal CFO LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-199	Closed	-$32.2K	–	78
2022 Q4	$32.2K	Buy	+199	New	+$30.5K	0.03%	162

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

My Personal CFO LLC's ABBV Position: Q1 2023 in Review

My Personal CFO LLC sold out of AbbVie (ABBV) in Q1 2023, closing a stake of 199 shares — an estimated $32.2K sold.

My Personal CFO LLC first reported a position in ABBV in Q4 2022 and held it in 1 quarter. The position peaked at $32.2K in Q4 2022. 3,139 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.

My Personal CFO LLC reported no remaining AbbVie position as of Q1 2023 after selling out during the quarter.
My Personal CFO LLC sold 199 AbbVie shares in Q1 2023, an estimated $32.2K.
My Personal CFO LLC first reported a position in AbbVie in Q4 2022 and held it in 1 quarter.
My Personal CFO LLC's AbbVie position peaked at $32.2K in Q4 2022.
3,139 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.

Based on My Personal CFO LLC's 13F filing for Q1 2023, filed 21 Apr 2023.